Outcomes and markers in the assessment of chronic obstructive pulmonary disease

被引:171
作者
Jones, PW
Agusti, AGN
机构
[1] St Georges Univ London, London SW17 0RE, England
[2] Hosp Univ Son Dureta, Serv Pneumol, Fdn Caubet Cimera, Palma de Mallorca, Spain
关键词
biological marker; chronic obstructive pulmonary disease; forced expiratory volume; physiological marker; symptomatic marker; validation;
D O I
10.1183/09031936.06.00145104
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The clinical presentation of chronic obstructive pulmonary disease (COPD) is highly variable, reflecting the interaction of a complex range of pathological changes including both pulmonary and systemic effects. The consequences of COPD experienced by the patient (i.e. its outcomes) include: symptoms, weight loss, exercise intolerance, exacerbations, health-related quality of life, health resource use and death. No single measure can reflect the variety of pathological effects or adequately describe the nature or severity of COPD. Currently, there are few validated markers for assessing COPD and evaluating the effectiveness of treatment. The forced expiratory volume in one second has been used as a global marker of COPD, but it does not fully reflect the burden of COPD on patients. New markers are needed to better characterise the full clinical spectrum of the disease and to guide the development and assessment of new and more effective therapies. This article considers the distinction between outcomes and markers, the various ways in which markers are used and the need for new markers in the management of chronic obstructive pulmonary disease. The process of marker selection and validation is reviewed and potential new biological, physiological and symptomatic markers for chronic obstructive pulmonary disease are assessed.
引用
收藏
页码:822 / 832
页数:11
相关论文
共 83 条
[1]   Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease [J].
Agustí, AGN ;
Sauleda, J ;
Miralles, C ;
Gomez, C ;
Togores, B ;
Sala, E ;
Batle, S ;
Busquets, X .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (04) :485-+
[2]   Systemic effects of chronic obstructive pulmonary disease [J].
Agustí, AGN ;
Noguera, A ;
Sauleda, J ;
Sala, E ;
Pons, J ;
Busquets, X .
EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (02) :347-360
[3]  
Andrich D, 1998, RASCH MODELS MEASURE
[4]  
[Anonymous], 2004, STAND DIAGN MAN PAT
[5]   EFFECTS OF SMOKING INTERVENTION AND THE USE OF AN INHALED ANTICHOLINERGIC BRONCHODILATOR ON THE RATE OF DECLINE OF FEV(1) - THE LUNG HEALTH STUDY [J].
ANTHONISEN, NR ;
CONNETT, JE ;
KILEY, JP ;
ALTOSE, MD ;
BAILEY, WC ;
BUIST, AS ;
CONWAY, WA ;
ENRIGHT, PL ;
KANNER, RE ;
OHARA, P ;
OWENS, GR ;
SCANLON, PD ;
TASHKIN, DP ;
WISE, RA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (19) :1497-1505
[6]  
Bankier Alexander A, 2002, Crit Rev Comput Tomogr, V43, P399
[7]   A comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma [J].
Barley, EA ;
Jones, PW .
EUROPEAN RESPIRATORY JOURNAL, 1999, 14 (03) :591-596
[8]   Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease [J].
Belman, MJ ;
Botnick, WC ;
Shin, JW .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 153 (03) :967-975
[9]   Functional status and survival following pulmonary rehabilitation [J].
Bowen, JB ;
Votto, JJ ;
Thrall, RS ;
Haggerty, MC ;
Stockdale-Woolley, R ;
Bandyopadhyay, T ;
ZuWallack, RL .
CHEST, 2000, 118 (03) :697-703
[10]   Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial [J].
Calverley, P ;
Pauwels, R ;
Vestbo, J ;
Jones, P ;
Pride, N ;
Gulsvik, A ;
Anderson, J ;
Maden, C .
LANCET, 2003, 361 (9356) :449-456